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OBJECTIVE—There is evidence of gut barrier and immune
system dysfunction in some patients with type 1 diabetes,
possibly linked with exposure to dietary wheat polypeptides
(WP). However, questions arise regarding the frequency of
abnormal immune responses to wheat and their nature, and it
remains unclear whether such responses are diabetes speciﬁc.
RESEARCH DESIGN AND METHODS—In type 1 diabetic
patients and healthy control subjects, the immune response of
peripheral CD3
 T-cells to WPs, ovalbumin, gliadin, -gliadin
33-mer peptide, tetanus toxoid, and phytohemagglutinin was
measured using a carboxyﬂuorescein diacetate succinimidyl
ester (CFSE) proliferation assay. T–helper cell type 1 (Th1), Th2,
and Th17 cytokines were analyzed in WP-stimulated peripheral
blood mononuclear cell (PBMNC) supernatants, and HLA was
analyzed by PCR.
RESULTS—Of 42 patients, 20 displayed increased CD3
 T-cell
proliferation to WPs and were classiﬁed as responders; prolifer-
ative responses to other dietary antigens were less pronounced.
WP-stimulated PBMNCs from patients showed a mixed proin-
ﬂammatory cytokine response with large amounts of IFN-,
IL-17A, and increased TNF. HLA-DQ2, the major celiac disease
risk gene, was not signiﬁcantly different. Nearly all responders
carried the diabetes risk gene HLA-DR4. Anti-DR antibodies
blocked the WP response and inhibited secretion of Th1 and
Th17 cytokines. High amounts of WP-stimulated IL-6 were not
blocked.
CONCLUSIONS—T-cell reactivity to WPs was frequently
present in type 1 diabetic patients and associated with HLA-DR4
but not HLA-DQ2. The presence of an HLA-DR–restricted Th1
and Th17 response to WPs in a subset of patients indicates a
diabetes-related inﬂammatory state in the gut immune tissues
associated with defective oral tolerance and possibly gut barrier
dysfunction. Diabetes 58:1789–1796, 2009
T
he gastrointestinal tract contains the largest col-
lection of immune cells in the body. In healthy
individuals, the gut immune system does not
normally mount an immune response against
molecules from foods and commensal bacteria, preferring
a default state of immune unresponsiveness called oral
tolerance (1).
When oral tolerance is broken, an immune imbalance
results that can lead to increased gut permeability, inﬂam-
mation, and tissue damage. The best understood example
of this is celiac disease, which is the classic food-induced
autoimmune disorder and the only autoimmune disease
for which the autoantigen (tissue transglutaminase) and
the inciting environmental factors (gluten proteins) are
known (2). In celiac disease, speciﬁc wheat gliadin pep-
tides undergo deamidation by gut mucosal tissue transglu-
taminase and are presented to T-cells on HLA-DQ2 or
HLA-DQ8 molecules, resulting in the stimulation of a
T–helper cell type 1 (Th1)-biased proinﬂammatory attack
that causes villous atrophy (2). It has also been proposed
that the gut and dietary antigens play an important role in
human type 1 diabetes, based on animal studies, epidemi-
ological reports, and a small number of studies on human
tissue (3–5).
The gut barrier and immune system in diabetes-prone
rodents display abnormalities similar to those of celiac
disease. For example, there are signs of enteropathy in
BBdp rats (6) and NOD mice (7) and inﬂammatory cyto-
kines in the gut are increased (8,9), as is permeability
before islet inﬂammation (10–12). Closing gut-tight junc-
tions prevents diabetes in the rat (12), there is increased
antibody and T-cell response to dietary antigens (13,14),
and wheat-based diets are major promoters of diabetes in
rats and mice (4). Diabetes appearance can be partly
inhibited by early neonatal feeding of small amounts of
wheat proteins to BBdp rats by dampening the proinﬂam-
matory state of the gut (8). There are also indications that
a gluten-free diet can enhance islet mass in BB rats (15).
High-risk children on a gluten-free diet for 6 months
showed enhanced ﬁrst-phase insulin response during an
intravenous glucose tolerance test, which could be an
indication of increased -cell mass and/or function (16,17).
Thus, wheat is one external factor that could inﬂuence the
development of diabetes.
Normal regulation of the gut immune system depends
on maintaining the integrity of the gut barrier (18). There
are now several reports of gut inﬂammation and signs of
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(19–24). T-cells from human diabetic pancreas display gut
mucosal homing properties (25), and T-cells reactive
against the diabetes autoantigen GAD express the gut-
associated homing receptor 47-integrin (26). In two
prospective analyses of high-risk children, early exposure
to cereals including wheat increased the risk of islet
autoimmunity (27,28). Another study showed increased
T-cell proliferation in response to high concentrations of
wheat gluten in 24% of patients (29). Auricchio et al. (30)
reported inﬂammation and increased immune response to
gliadin in jejunal biopsies from patients. Approximately
2–6% of patients with type 1 diabetes have celiac disease,
a rate that is several times higher than in the general
population, and a recent report indicated that celiac
disease patients on a gluten-free diet were protected from
later development of type 1 diabetes (31). These ﬁndings
point to both a loss of barrier integrity and dysregulation
in the gut immune system.
Thus, questions arise regarding the frequency of abnor-
mal immune responses to wheat and their nature, and it
remains unclear whether such responses are diabetes
related, reﬂect a separate gut dysfunction, or are simply
due to shared celiac risk genes, such as HLA-DQ2, HLA-
DQ8, and HLA-DR3. The number of studies examining the
response of immune cells to wheat proteins in type 1
diabetic patients is limited (20,29,30), and it remains
unclear whether there is a genetically determined abnor-
mal immune response to wheat in humans at risk for type
1 diabetes. We favor the view that there is a diabetes-
speciﬁc abnormal immune response to wheat in some
patients that is not explained by shared celiac disease risk
genes.
We hypothesize that in some type 1 diabetic patients,
excessive amounts of wheat proteins/polypeptides enter
the body through a leaky gut barrier and promote an
abnormal immune response that breaks oral tolerance and
stimulates immune cells that are involved in type 1 diabe-
tes pathogenesis (4). As a ﬁrst step, it is important to
clarify what proportion of patients with type 1 diabetes
display abnormal immune reactivity to dietary wheat
polypeptides (WPs) and to characterize this abnormal
response. The objectives of the present study were to
determine whether patients with type 1 diabetes display
increased T-cell proliferation in response to a mixture of
WPs, to analyze the pattern of cytokines produced, and to
determine whether this reactivity is associated with spe-
ciﬁc HLA alleles.
RESEARCH DESIGN AND METHODS
Type 1 diabetic patients were recruited through physicians at The Ottawa
Hospital and the Children’s Hospital of Eastern Ontario, Ottawa, Canada. All
patients have clinically proven type 1 diabetes. The majority of the 42 subjects
were young adults of both sexes, with one child included. A total of 22
unrelated control subjects of a similar age range and ethnic group (Caucasian)
without acute infection or autoimmune disease were recruited (Table 1). All
individuals included in the study were negative for tissue transglutaminase
antibody, as measured by the Ottawa Hospital Clinical Laboratory. Blood was
obtained by venepuncture from patients and healthy control subjects with
informed consent. The local ethics committees approved the study.
Isolation of mononuclear cells, tissue culture, and antigen response.
Peripheral blood mononuclear cells (PBMNCs) were isolated by density
gradient centrifugation over Ficoll (Histopaque 1.077; Sigma Aldrich, Oakville,
ON, Canada). Cells were washed twice with Hank’s buffer (Invitrogen,
Burlington, ON, Canada) containing 20 mmol/l HEPES (Invitrogen). PBMNCs
(20  10
6/ml) were labeled with 2 mmol/l carboxyﬂuorescein diacetate
succinimidyl ester (CFSE) (Invitrogen) for 20 min and incubated at 37°C in 5%
CO2. Cells were washed twice with Hank’s buffer containing 5% pooled human
AB
 serum (Bioreclamation, Hicksville, NY) and ﬁnally diluted in RPMI-1640
(Sigma Aldrich) containing 5% human AB
 serum, 2 mmol/l L-glutamine
(Invitrogen), 25 mmol/l HEPES (Invitrogen), 50 mol/l -mercaptoethanol
(Sigma Aldrich), and 1% antibiotic/antimycotic (Invitrogen). Cells were cul-
tured with various concentrations of wheat protein/peptides (chymotrypsin-
treated, heat-inactivated WP; ICN Biochemicals, Cleveland, OH [32]) (3.1–12.4
g/ml), 10 g/ml gliadin (Sigma Aldrich), 10 g/ml -gliadin 33-mer peptide (a
generous gift from Dr. Chaitan Khosla, Stanford University, Stanford, CA, and
Dr. Hubert Kolb, German Diabetes Center, Du ¨sseldorf, Germany), 10 g/ml
insulin (Sigma Aldrich), 1 mol ovalbumin (Sigma Aldrich), 2.7 LF/ml tetanus
toxoid (Connaught Laboratory, Toronto, ON, Canada), or 5 g/ml phytohe-
magglutinin (Sigma Aldrich). 1.2  10
6 cells in 1 ml/well were cultured in
24-well plates (Falcon; VWR, Mississauga, ON, Canada). After 3 days of
culture, 10 IU/ml recombinant human interleukin (IL)-2 (PeproTech, Rocky
Hill, NJ) was added to each well. On day 8, supernatants were harvested and
cell proliferation was assessed using a CFSE-based, ﬂow cytometric assay
with results expressed as the cell division index (CDI) (deﬁned as the number
of CD3
 CFSE
dim cells cultured with antigen/number of CD3
 CFSE
dim cells
without antigen; the number of CFSE
dim events was the number correspond-
ing to 5,000 CFSE
bright cells) (33).
Wheat protein preparations were analyzed for lipopolysaccharide (LPS).
The concentration was low and comparable with other recombinant proteins.
The addition of the LPS inhibitor polymyxin B (Sigma) had no effect on
WP-induced T-cell proliferation but blocked LPS-induced T-cell proliferation
(supplementary Fig. S1, available in an online appendix at http://diabetes.
diabetesjournals.org/cgi/content/full/db08-1579/DC1).
Blocking of HLA-DR with anti-DR antibody. Inhibition of the proliferation
of PBMNCs to wheat protein was studied by adding monoclonal anti-DR
antibodies (clone G46-6 and mouse IgG2a,; BD Biosciences, Mississauga, ON,
Canada) to the culture 30 min before adding wheat protein to the cell culture
wells. The mouse IgG2a, isotype antibody (BD Biosciences) was used as a
control. Both antibodies were used at a concentration of 5 g/ml.
Cytokine evaluation in culture supernatants. Cytokines including IL-4,
IL-6, IL-10, tumor necrosis factor (TNF), and -interferon (IFN-) were
quantiﬁed simultaneously using a human Th1/Th2 cytokine cytometric bead
array (CBA) kit. The CBA kit and CBA software were purchased from BD
Biosciences. All assays were performed according to the manufacturer’s
protocol, and samples were read in a Coulter FC500 ﬂow cytometer after
appropriate calibration. Quantiﬁcation of cytokine levels was performed by
comparison with standards provided in the kit using CBA software. IL-17A
was analyzed in supernatants of PBMNC from a subset of patients and healthy
control subjects in the presence or absence of anti-DR antibodies using an
enzyme-linked immunosorbent assay (ELISA) kit purchased from eBioscience
(San Francisco, CA).
HLA typing. HLA-DR and -DQ haplotypes of subjects were characterized by
PCR-based HLA class II tissue typing using low resolution Olerup SSP typing
kits for HLA-DR and -DQ (Genovision, West Chester, PA) or by the Ottawa
Hospital Clinical Laboratory.
Statistical analysis. Differences in CDI among patients and control subjects
were analyzed by the nonparametric Mann-Whitney U test using GraphPad
Prism (version 4.03 for Windows; GraphPad Software, San Diego, CA).
Signiﬁcance of differences in frequencies was evaluated using Fisher’s exact
two-tailed test. Spearman’s correlation was used to analyze the correlation
between WP T-cell response and the other dietary or autoantigens using
STATISTICA (version 6; Statsoft, Tulsa, OK).
RESULTS
CD3
 T-cell response to WPs in control and type 1
diabetic subjects. The CFSE assay permitted evaluation
of T-cell proliferation to low, nontoxic concentrations of
TABLE 1
Description of control subjects and patients with type 1 diabetes
Group n
Sex ratio
(female/male) Age
Duration of
diabetes
(years)
Type 1 diabetic
patients 42 28/14 26.7 (8–41) 11.2  7
Healthy control
subjects 22 11/11 24.5 (18–32) NA
Data are means (range) or means  SD unless otherwise indicated.
NA, not applicable.
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 T-cell proliferation in the presence of
3.1 and 6.2 g/ml WP was signiﬁcantly higher in the type 1
diabetic patient group compared with control subjects
(Fig. 1). At 12.4 g/ml, CDI was still higher in the type 1
diabetic patient group but the response was less than at 6.2
g/ml, suggesting inhibition. Therefore, 6.2 g/ml was
chosen as the optimum concentration. To identify patients
with a positive proliferation response to WP, the mean 
3 SD of the control group CDI (CDI 14.6) was chosen as
the cutoff. Of the 42 patients with type 1 diabetes, 20 (47%)
had a positive proliferation response to WP. In an ex-
panded analysis of two responders, the proliferative re-
sponse to WP was mainly from CD4
 T-cells with only a
weak CD8
 T-cell response (data not shown). The distri-
bution of CDI to WP was signiﬁcantly different between
patients (n 	 42) and control subjects (n 	 22); for
patients, the median was 11.8 (range 1.0–323) and for
control subjects 4.5 (0.8–12.8) (P 	 0.0004; Mann-Whitney
U test) (Fig. 1).
The mean  SD CDI was 32  60 for patients and 4.9 
3.2 for control subjects. WP response was not correlated
with duration of disease, but there was a moderate inverse
correlation with age (r 	
 0.35, P 	 0.025; data not
shown). When a subgroup of six control subjects was
matched with 19 patients for HLA-DR4, age, and sex, the
increased T-cell proliferation in response to WP in the type
1 diabetic patient group remained signiﬁcant (P 	 0.038)
(supplementary Fig. S2).
T-cell responses to other dietary antigens moder-
ately increased in type 1 diabetic patients. Some
patients displayed increased T-cell responses to other
dietary antigens including ovalbumin, an irrelevant dietary
antigen, and to the celiac-related antigens (wheat gliadin
and -gliadin 33-mer peptide) as well as the type 1 diabetes
autoantigen insulin (P 	 0.02, P 	 0.03, P 	 0.001, and P 	
0.03, respectively) (Fig. 2). We did not ﬁnd signiﬁcant
differences between type 1 diabetic patients and control
subjects in response to the recall antigen, tetanus toxoid,
or the T-cell mitogen phytohemagglutinin (P 	 0.2) (Fig.
2). There was a positive correlation between WP T-cell
responses and T-cell responses to ovalbumin, gliadin, and
-gliadin 33-mer peptide in type 1 diabetic patients (P 	
0.01, P 	 0.002, and P 	 0.0001; data not shown). In
contrast, we detected a weak, nonsigniﬁcant correlation
between WP T-cell response and insulin T-cell response in
type 1 diabetic patients (P 	 0.06; data not shown).
High concentration of IFN-, IL-6, and IL-17A in
supernatants of WP-stimulated PBMNC. Cytokines se-
creted by WP-stimulated PBMNC were analyzed in the
culture supernatant using ﬂow CBAs or ELISA (IL-17A)
(Fig. 3). The concentration of the proinﬂammatory cyto-
kines IFN-, TNF, and IL-6 was higher in WP-stimulated
PBMNC from type 1 diabetic patients (P 	 0.03, P 	 0.008,
and P 	 0.001, respectively), whereas the counter inﬂam-
matory cytokines IL-4 and IL-10 were not different. Remov-
ing one control subject from the IL-4 group analysis
(circled symbol, Fig. 3) revealed signiﬁcantly higher IL-4
concentration in the type 1 diabetic patient supernatants.
However, the concentration of IL-4 was much lower
than that of IFN-. The concentration of IL-17A in
WP-stimulated PBMNC culture supernatants from pa-
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FIG. 1. Antigen-speciﬁc CD3
 T-cell proliferation. 1.2  10
6 CFSE-
labeled PBMNCs from patients with type 1 diabetes (T1D) or healthy
control subjects were cultured for 8 days in the absence or presence of
different concentrations of WPs. On day 8, cells were stained with
Cy-chrome conjugated anti-CD3 monoclonal antibody. CDI was calcu-
lated based on a ﬁxed number of 5,000 CD3
 CFSE
bright cells using the
following formula: CDI  number of CD3
, CFSE
dim cells with antigen/
number of CD3
, CFSE
dim cells without antigen (medium). The hori-
zontal line indicates the mean.
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FIG. 2. T-cell proliferation in response to WPs and other antigens or mitogen. 1.2  10
6 CFSE-labeled PBMNCs from patients with type 1 diabetes
(T1D) or healthy control subjects were cultured for 8 days in the absence or presence of WP, ovalbumin (OVA), gliadin, 33-mer, insulin, tetanus
toxoid (TT), or phytohemagglutinin (PHA) (see RESEARCH DESIGN AND METHODS for details). On day 8, cells were stained with Cy-chrome–conjugated
anti-CD3 monoclonal antibody. CDI was calculated. A CDI value greater than the control mean  3 SD (CDI >14.6) was used to deﬁne a positive
response to WP. P values indicate statistical difference compared with control subjects. The horizontal lines indicate the means.
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(P 	 0.02) (Fig. 3).
Association of HLA-DR4 risk alleles for type 1 diabe-
tes with immunity to WPs. We analyzed HLA-DR and
-DQ haplotypes in patients with type 1 diabetes and
control subjects. The frequency of HLA haplotypes in the
control group was similar to previously published refer-
ence populations (34) (data not shown). HLA-DRB1*03
and -DRB1*04, which are associated with type 1 diabetes,
were more frequent in type 1 diabetic patients compared
with control subjects. Heterozygous DR3/DR4 individuals
represented 29% of our type 1 diabetic patients, but none
of our control subjects was heterozygous for HLA-DR3/
DR4 (data not shown). In addition, we compared the
frequency of risk alleles in type 1 diabetic patients who
were either responders or nonresponders to WP (Table 2).
Type 1 diabetic responders to WP carried HLA-DRB1*04 in
95% of cases, which was signiﬁcantly higher than in the
nonresponders (59%; P 	 0.01) (Table 2). Distribution of
T-cell proliferation (CDI) to WP in type 1 diabetic patients
with HLA-DRB1*03 or HLA-DRB1*04 or in those heterozy-
gous for HLA-DRB1*03/*04 is shown in Fig. 4. One of seven
type 1 diabetic patients with HLA-DRB1*03
/*04

 showed
positive responses to WP. In contrast, 10 of 20 type 1
diabetic patients who carried one risk allele HLA-DRB1*04
or 9 of 12 patients who carried both risk genes HLA-
DRB1*03/*04 showed positive reactivity to WP.
The frequency of HLA-DQ2, the major celiac disease–
associated allele, was not signiﬁcantly different between
type 1 diabetic patients and control subjects (P 	 0.6; data
not shown). Importantly, the difference for HLA-DQ2
between responders and nonresponders was not signiﬁ-
cant (P 	 0.75) (Table 2). We also evaluated the HLA-DR
and -DQ haplotypes by high-resolution analysis in type 1
diabetic patients. A positive response to WP in patients
was more frequently associated with the HLA-DR4
(DRB1*0401/4) DQB1*0301/2 haplotype, and HLA-DR3/
DQB1*0201 appeared to magnify the response (Fig. 4).
Patients who were HLA-DQ3
 were also more likely to be
responders (Table 2).
T-cell responses to WP inhibited by monoclonal
anti-DR antibodies. To conﬁrm the role of HLA-DR in
the T-cell response to WP, we evaluated the blocking effect
of anti–HLA-DR monoclonal antibodies on PBMNC of 14
type 1 diabetic patients. Monoclonal anti-DR antibodies
blocked T-cell responses to WPs in type 1 diabetic pa-
tients, whereas isotype control antibody did not prevent
the T-cell response (Fig. 5A). Anti–HLA-DR4 antibody had
only a small inhibitory effect on T-cell response to tetanus
toxoid (supplementary Fig. S3). CBA cytokine analysis of
the culture supernatants from WP-stimulated PBMNC of
type 1 diabetic patients showed that monoclonal anti-DR
antibody signiﬁcantly inhibited secretion of Th1 cytokines
but not Th2 cytokines (Fig. 5B). WP-induced production of
IL-17A was also blocked by the addition of anti-DR (P 	
0.008) (Fig. 5B).
DISCUSSION
The foods we eat contain numerous nonself molecules
that do not normally stimulate a proinﬂammatory immune
response in healthy individuals (35). In some diabetes-
prone rodents (6,7,10) and humans (19,21–23), there is
evidence that the gut mucosa is mildly inﬂamed and the
epithelial barrier is leaky, providing a potential entry point
for nonself antigens in the context of a proinﬂammatory
cytokine imbalance that could promote autoimmunity
(4,18). The present results support this view. Although the
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FIG. 3. WP-stimulated cytokine secretion by PBMNC at day 8 of culture. Box and Whisker plots with individual values for control and diabetic
subjects. IFN-, TNF, IL-6, IL-4, and IL-10 were measured by ﬂow CBA. IL-17A was measured by ELISA. Each plot includes the mean (dashed line),
median (solid line), distribution, and range. (For IL-4, the difference between control and type 1 diabetic [T1D] subjects is signiﬁcant when the
circled outlier value in the control group is removed [P  0.03].)
TABLE 2
HLA-DR and -DQ in type 1 diabetic responders and nonresponders
n DR3 DR4 DR3/DR4 DQ2 DQ3
Nonresponders 22 41 59 14 41 64
Responders 20 50 95 (P 	 0.01) 45 (P 	 0.04) 50 (P 	 0.75) 95 (P 	 0.02)
Data are % unless otherwise indicated. T-cell proliferation (CDI) to WP was evaluated in type 1 diabetic patients. Patients with a CDI value
greater than mean  3 SD of the control group (CDI 14.6) were classiﬁed as responders. Those below were classiﬁed as nonresponders.
The percentage of individuals with the indicated HLA haplotypes in these groups was calculated.
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drive the -cell–speciﬁc autoimmune response is not
known, diet is an important factor inﬂuencing diabetes
outcome, possibly by supplying a constant source of
stimulatory antigens to the gut immune system (4).
There was moderately increased T-cell proliferative
response to other dietary antigens such as ovalbumin,
gliadin, and the celiac toxic gliadin 33-mer peptide (Fig. 2),
but this was less pronounced than the response to WP.
These data suggest a general impairment of oral tolerance
in some type 1 diabetic patients (36), with the strongest
and most frequent abnormal proliferative response in-
duced by the mixture of WPs.
We are aware of only one other study of WP response in
patient PBMNCs (29). Klemetti et al. (29) showed an
increased cell-mediated immune response to high concen-
trations of wheat gluten (400 g/ml) in 24% of newly
diagnosed type 1 diabetic patients. The proliferative re-
sponses in this study were low compared with those in the
present study, possibly as a result of the high polypeptide
concentration, different gluten fractions, culture condi-
tions, proliferation assay, and/or different genetic back-
ground of the subjects as well as different duration of
diabetes. In keeping with reports that high concentrations
of gliadin are cytotoxic (37), we found that 25 g/ml of
wheat protein extract inhibited response of PBMNC,
whereas 6.2 g/ml was optimum for our assay (29). The
CFSE assay used here not only permits identiﬁcation of
individual cell populations by ﬂow cytometry but is also
more sensitive than the thymidine assay (33). Therefore, the
present analysis permitted us to detect wheat-speciﬁc CD3

T-cell proliferation using a low, noninhibitory dose of WP.
Additional evidence linking the development of diabetes
in humans to wheat comes from epidemiological studies
(27,28) and reports of immune responses of patient tissues
to WP (29,30). Anti-gliadin antibodies have been reported
in newly diagnosed children with type 1 diabetes (38), and
prospective studies of infants at high risk indicate that
early exposure to cereals, particularly wheat, was linked
to appearance of islet autoantibodies (27,28). Further-
more, a signiﬁcant subset of type 1 diabetic patients
displays celiac disease autoantibodies (39). CD3
 lamina
propria and intestinal epithelial lymphocytes were in-
creased in 20% of type 1 diabetic patients receiving rectally
instilled gliadin (40). Immunohistochemical evaluation
and culture of jejunal biopsies from tissue transglutami-
nase antibody–negative type 1 diabetic children with WP
increased frequency of activated CD25
 cells in the lamina
propria as well as expression of HLA-DR in the crypts in
association with enhanced inﬁltration of the epithelium by
CD3
 cells (30). Therefore, the present results are consis-
tent with those of Auricchio et al. (30) showing that a
subset of type 1 diabetic patients displayed signs of
inﬂamed gut mucosa and increased immune reactivity to
WPs.
Type 1 diabetes has been traditionally thought of as a
T-cell–mediated disease associated with high levels of the
Th1 cytokine IFN-. It now seems likely that type 1
diabetes is the result of dysregulation within a broader
network of immune cell types (41). For example, the role
of the recently discovered Th17 cells and the extent to
which there is a dysregulation of communication be-
tween Th1, Th2, and Th17 cells in human diabetes
remain unclear. We observed WP-induced T-cell prolif-
eration in nearly half of our type 1 diabetic patients but
not in healthy control subjects. This response was mixed
in nature, accompanied by increased production of proin-
ﬂammatory cytokines IFN-, TNF, IL-6, and IL-17A as well
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FIG. 4. Graphic representation of the relationship between wheat-induced T-cell response and high-resolution HLA diabetes risk alleles. Box and
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range. A: Distribution of T-cell proliferation (CDI) to WP in type 1 diabetic patients with HLA-DRB1*03 and HLA-DRB1*04 or in those
heterozygous for HLA-DRB1*03/*04. A CDI value greater than mean  3 SD of the control group (CDI >14.6, dashed line) was used to deﬁne a
positive proliferation response. One of the type 1 diabetic patients with HLA-DRB1*03
/*04
 showed positive responses to WP (E). Type 1
diabetic patients who carried one risk allele HLA-DRB1*04 (10 of 20) or patients who carried both risk genes HLA-DRB1*03/*04 (9 of 12) showed
positive reactivity to WP. High-resolution results of HLA-DR are labeled beside each individual. B: Distribution of T-cell proliferation (CDI) to
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of the 42 type 1 diabetic individuals are neither DR3 nor DR4, and therefore they are not included in this ﬁgure. One of the seven individuals with
DR3/non-DR4 in the left panel is heterozygous for DQ*02/*03 and was therefore placed in the middle column in the right panel [DQ*02*03].
Differences in high-resolution haplotypes between responders and nonresponders were not evaluated statistically because of the small sample
size.)
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concentrations of IFN- and IL-17A suggest that Th1 and
Th17 cytokine–producing, WP-responsive CD3
 cells were
activated in association with a proinﬂammatory condition
in the gut (6,30). IL-6 was present in WP culture superna-
tants at very high levels, four to six times those of IFN-.
TNF was also increased but to a much lesser extent. IL-6
and TNF are proinﬂammatory cytokines that promote the
secretion of IL-17 by Th17 cells and block the production
of Foxp3
 regulatory T-cells (42). We did not observe a
signiﬁcant increase in IL-10 in response to WP, making it
unlikely that IL-17 originated from Th17 regulatory cells
that produce both IL-10 and IL-17. It seems unlikely that
such high amounts of IL-17 could originate from CD8

T-cells because expansion of WP-responsive T-cells was
predominantly from CD4
 cells and IL-17A production
was blocked by anti-DR antibody.
High levels of IFN- were produced in response to WP,
whereas the concentration of the Th2 cytokine IL-4, al-
though signiﬁcantly increased, was only one-third that of
IFN-, suggesting a predominance of Th1 over Th2 cells.
Although both of these cytokines can inhibit development
of Th17 cells from naive precursors (42), it has been
suggested that committed Th17 cells are not affected (41).
Therefore, we favor the interpretation that WP stimulates
the production of IL-17A from previously committed Th17
cells. While IL-17A can be produced under certain circum-
stances by CD8
 T-cells and members of the innate
immune system (T-cells and natural killer T-cells), Th17
cells are the major producers of IL-17A. Thus, the overall
cytokine pattern observed in WP-stimulated PBMNC from
type 1 diabetic patients suggests a predominant Th1 and
Th17 proinﬂammatory state consistent with the specula-
tion that autoimmunity can occur when there is inappro-
priate cross-regulation between Th1 and Th17 cytokine
networks (42).
The role of IL-6 in type 1 diabetes remains controversial
(43). In the present study, patient PBMNC cultured with
WP secreted large amounts of IL-6, the origin of which is
presently unclear. Nonetheless, some points are worth
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 and not CD8

cells, most responders were HLA-DR4
, and treatment
with anti-DR did not block production of IL-6. These
results suggest that IL-6 originated from non–T-cells. Oth-
ers report that IL-6 gene expression was upregulated
threefold in monocytes from adult-onset type 1 diabetic
subjects (44). Furthermore, overexpression of IL-6 in
pancreas was correlated with islet inﬂammation, which
could contribute to the development of autoimmune dis-
ease (43). The high concentration of WP-induced IL-6
further supports our previous proposal of a potential
mechanism by which wheat can promote the development
of diabetes involving induction of proinﬂammatory cyto-
kines such as IL-6, IFN-, and TNF- by wheat antigens
(4,9,13,45).
The HLA genes are the major genetic determinant of
type 1 diabetes. More than 90% of Caucasian type 1
diabetic patients carry either HLA-DR3 or HLA-DR4 hap-
lotype, and a synergistic effect on type 1 diabetes risk is
observed in HLA-DR3/4 heterozygous individuals (46).
Patients with type 1 diabetes and celiac disease share
some HLA-associated risk genes such as HLA-DQ2 (HLA-
DQB1*02) and HLA-DQ8 (HLA-DQB1*0302). The fre-
quency of HLA risk genes is different between the two
diseases: 90–95% of celiac disease patients are HLA-DQ2
and 5–10% are HLA-DQ8 (47), whereas up to 50% of
diabetic patients are HLA-DQ8/DQ2 heterozygous (48). In
our type 1 diabetic population, increased immune re-
sponse to WPs was not explained by shared genetic risk
for celiac disease. The frequency of HLA-DQB1*02 was not
signiﬁcantly different between type 1 diabetic patients and
control subjects (P 	 0.6), and we did not detect any
signiﬁcant differences for HLA-DQB1*02 between WP re-
sponders and nonresponders (P 	 0.75) (Table 2). We also
evaluated the HLA-DR and -DQ haplotype by high-resolu-
tion analysis in type 1 diabetic patients. A positive re-
sponse to WP in patients was more frequently associated
with the HLA-DR4 (DRB1*0401/4) DQB1*0301/2 haplo-
type, and HLA-DR3/DQB1*0201 appeared to magnify the
response (Table 2, Fig. 4).
A genetic basis for WP response in type 1 diabetic
patients is suggested by the ﬁnding that T-cell proliferation
and inﬂammatory cytokine production were blocked by
anti-DR antibodies and responders were nearly all HLA-
DR4
. Others have observed enhanced expression of
HLA-DR in the intestinal mucosa of children with type 1
diabetes (20,30), and gluten-induced T-cell proliferation
was blocked by anti-DR antibodies in two patients in a
previous study (29). Importantly, WP-induced T-cell pro-
liferation was not explained by an overrepresentation of
the major celiac disease risk gene HLA-DQ2. HLA-DQ2
prevalence was not different between patients and control
subjects or between WP responder and nonresponder
patient groups, and the T-cell response was not attribut-
able to the presence of subclinical celiac disease given that
all our patients with type 1 diabetes were negative for
antibodies against the pathognomic celiac disease autoan-
tigen, tissue transglutaminase. These ﬁndings are consis-
tent with other reports showing that the gut inﬂammation
observed in type 1 diabetic patients is different from that
seen in patients with celiac disease (20,49) and not neces-
sarily related to HLA-DQ2 or HLA-DQ8 (30). Therefore, the
tolerogenic function of the gut immune system with re-
spect to WPs was compromised in a large subset of
patients with type 1 diabetes in an HLA-DR–restricted,
diabetes-speciﬁc manner.
In summary, almost half of our type 1 diabetic patients
displayed increased proliferation when PBMNCs were
cultured in vitro with nontoxic concentrations of WP. The
cytokine pattern was mixed having characteristics of a
predominant Th1 and Th17 response with a lesser contri-
bution of the Th2 cytokine IL-4. The WP proliferative
response occurred mainly in HLA-DR4 individuals and was
blocked with anti-DR antibodies but was not due to the
major celiac disease gene HLA-DQ2. This demonstrated
the presence of a mixed proinﬂammatory Th1/Th17 re-
sponse to dietary WPs that appeared to be diabetes
speciﬁc.
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